Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Revenue (2016 - 2023)

Perspective Therapeutics' Revenue history spans 14 years, with the latest figure at -$4.9 million for Q4 2023.

  • On a quarterly basis, Revenue changed N/A to -$4.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $613000.0, a N/A change, with the full-year FY2023 number at $1.4 million, changed N/A from a year prior.
  • Revenue hit -$4.9 million in Q4 2023 for Perspective Therapeutics, down from $2.2 million in the prior quarter.
  • Over the last five years, Revenue for CATX hit a ceiling of $2.9 million in Q1 2022 and a floor of -$4.9 million in Q4 2023.
  • Historically, Revenue has averaged $1.9 million across 5 years, with a median of $2.3 million in 2019.
  • Biggest five-year swings in Revenue: soared 49.69% in 2020 and later tumbled 40.12% in 2023.
  • Tracing CATX's Revenue over 5 years: stood at $2.2 million in 2019, then rose by 6.94% to $2.4 million in 2020, then rose by 19.37% to $2.8 million in 2021, then plummeted by 39.03% to $1.7 million in 2022, then tumbled by 385.5% to -$4.9 million in 2023.
  • Business Quant data shows Revenue for CATX at -$4.9 million in Q4 2023, $2.2 million in Q3 2023, and $1.5 million in Q2 2023.